These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21682772)

  • 1. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Stubbs JR; Wetmore JB
    Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary and tertiary hyperparathyroidism.
    Jamal SA; Miller PD
    J Clin Densitom; 2013; 16(1):64-8. PubMed ID: 23267748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
    Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ
    Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
    Cunningham J; Locatelli F; Rodriguez M
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pharmacotherapy for secondary hyperparathyroidism.
    Rodríguez M; Rodríguez-Ortiz ME
    Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].
    Torres PU
    Nephrol Ther; 2011 Apr; 7(2):99-104. PubMed ID: 21310676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization.
    de Francisco AL; Piñera C; Palomar R; Arias M
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S281-5. PubMed ID: 17130275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.